Estrogens, Conjugated (USP)
"Estrogens, Conjugated (USP)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.
Below are MeSH descriptors whose meaning is more general than "Estrogens, Conjugated (USP)".
Below are MeSH descriptors whose meaning is more specific than "Estrogens, Conjugated (USP)".
This graph shows the total number of publications written about "Estrogens, Conjugated (USP)" by people in this website by year, and whether "Estrogens, Conjugated (USP)" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Estrogens, Conjugated (USP)" by people in Profiles.
The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Menopause. 2023 01 01; 30(1):28-36.
Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women's Health Initiative Observational Study (WHI-OS). Menopause. 2021 07 26; 28(10):1108-1116.
Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause. 2021 05 03; 28(6):610-618.
Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst. 2017 09 01; 109(9).
Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013 Mar; 20(3):254-60.
Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol. 2009 Dec 20; 27(36):6135-43.
A confusing case of confusion. Acute porphyrias. J Okla State Med Assoc. 2008 Apr; 101(4):85-6, 89-90.
Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005 Sep 21; 97(18):1366-76.
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):953-62.
The IGF system in the neonatal ovine uterus. Reproduction. 2005 Mar; 129(3):337-47.